Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial Meeting Abstract


Authors: Sharman, J. P.; Coutre, S. E.; Furman, R. R.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; Ghia, P.; Hallek, M. J.; Coiffier, B.; O'Brien, S. M.; Tausch, E.; Kreuzer, K. A.; Jiang, W.; Jahn, T. M.; Lazarov, M.; Stilgenbauer, S.
Abstract Title: Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial
Meeting Title: 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 32
Issue: 15 Suppl.
Meeting Dates: 2014 May 30-Jun 3
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2014-05-20
Language: English
ACCESSION: WOS:000358613203829
PROVIDER: wos
Notes: Meeting Abstract: 7011^ -- Source: Wos
MSK Authors
  1. Andrew D Zelenetz
    547 Zelenetz